Auf dieser Seite
TECX Tectonic Therapeutic, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ 10-K/10-Q Aug 6, 2026
$20,07
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$15,5252-Wochen-Tief
$39,5352-Wochen-Hoch
Marktkapitalisierung (MRQ)
$386M
P/E
-5.0
EPS
$-4.05
Ihre Abzeichen
52W-Spanne
$16–$40
Analystenbewertung
BUY
Kursziel
$71
P/E
-5.0
ROE
-27.7%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
TECX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$20.07
Marktkapitalisierung (MRQ)
$386M
P/E
-5.0
EPS
$-4.05
ROE
-27.7%
52W-Spanne
$16–$40
TECX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 21. Juni 2024 | 1-for-12 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-4.052021-12-31 → 2025-12-31
Freier Cashflow$-60M2018-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | TECX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -5.05-Jahres-Durchschnitt ≈-6.5 | ≈-6.5 | · | · | |
| K/B (MRQ) | 1.75-Jahres-Durchschnitt ≈6.1 | ≈6.1 | 2.3 | Überbewertet | |
| Kurs / FCF (TTM) | -5.35-Jahres-Durchschnitt ≈-10.5 | ≈-10.5 | · | · | |
| Kurs / Cashflow (TTM) | -5.45-Jahres-Durchschnitt ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.55-Jahres-Durchschnitt ≈5.9 | ≈5.9 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | TECX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -35.8%5-Jahres-Durchschnitt ≈-40.6% | ≈-40.6% | -35.8% | Im Einklang | |
| ROE | -27.7%5-Jahres-Durchschnitt ≈-18.5% | ≈-18.5% | -45.6% | Spitzenklasse | |
| ROIC | -34.0% | · | -36.2% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | TECX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 22.35-Jahres-Durchschnitt ≈14.6 | ≈14.6 | 12.9 | Starke Liquidität | |
| Quick Ratio | 26.35-Jahres-Durchschnitt ≈14.1 | ≈14.1 | 9.6 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
4.4%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 19, 2026 | $-1.18 | $-1.38 | 14.6% |
| 31. März 2026 | $-1.34 | $-1.21 | -11.1% | |
| 31. Dezember 2025 | $-1.03 | $-1.13 | 8.5% | |
| 30. September 2025 | $-1.02 | $-1.07 | 4.5% | |
| 30. Juni 2025 | $-1.07 | $-1.00 | -6.9% | |
| 31. März 2025 | $-0.93 | $-1.11 | 16.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $63M | $41M | $37M | $72M | $83M | $87M | $55M | $35M | $15M | |
| SG&A Expense | $21M | $17M | $8M | $33M | $36M | $33M | $21M | $11M | $3M | |
| Operating Expenses | $84M | $58M | $45M | $105M | $119M | $120M | $76M | $46M | $18M | |
| Operating Income | $-84M | $-58M | $-45M | $-105M | $-119M | $-120M | $-76M | $-46M | $-18M | |
| Interest Income | $11M | $4M | $581.0K | · | · | $719.0K | $3M | $2M | $57.0K | |
| Other Non-op | $-119.0K | $-511.0K | $396.0K | $-456.0K | $-285.0K | $516.0K | $3M | $-118.0K | $-262.0K | |
| Pretax Income | $-73M | $-58M | · | · | · | · | · | · | · | |
| Income Tax | $1M | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-74M | $-58M | $-43M | $-106M | $-119M | $-120M | $-73M | $-46M | $-19M | |
| EPS (Basic) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 | · | · | · | · | |
| EPS (Diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 | · | · | · | · | |
| Shares (Basic) | 18,322,533 | 8,490,171 | 1,268,512 | 43,739,000 | 42,854 | · | · | · | · | |
| Shares (Diluted) | 18,322,533 | 8,490,171 | 1,268,512 | 43,739,000 | 42,854 | · | · | · | · | |
| EBITDA | $-83M | $-56M | $11M | $-104M | $-117M | $-119M | $-75M | $-46M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $254M | $141M | $29M | $93M | $190M | $260M | $187M | $126M | $6M | |
| Prepaid Expense | $3M | $6M | $2M | $7M | $10M | $8M | $9M | $4M | $345.0K | |
| Other Current Assets | · | · | $570.0K | $1M | $2M | $271.0K | $344.0K | $795.0K | $60.0K | |
| Current Assets | $257M | $147M | $31M | $100M | $199M | $267M | $196M | $130M | $6M | |
| PP&E (Net) | $1M | $2M | $3M | $3M | $4M | $3M | $4M | $3M | $349.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $7M | $8M | $5M | $5M | $3M | $394.0K | |
| Accum. Depreciation | $3M | $3M | $2M | $4M | $4M | $2M | $1M | $384.0K | $45.0K | |
| Other Non-current Assets | $640.0K | $156.0K | $31.0K | $40.0K | $74.0K | $436.0K | $625.0K | $825.0K | $365.0K | |
| Total Assets | $261M | $153M | $39M | $104M | $204M | $271M | $201M | $133M | $7M | |
| Accounts Payable | $1M | $976.0K | $409.0K | $384.0K | $3M | $3M | $4M | $3M | $527.0K | |
| Accrued Liabilities | $7M | $8M | $8M | $12M | $16M | $14M | $10M | $8M | $2M | |
| Current Liabilities | $10M | $12M | $41M | $13M | $19M | $17M | $14M | $11M | $3M | |
| Capital Leases | $0 | $132.0K | $2M | $188.0K | $0 | · | · | · | · | |
| Deferred Tax | · | · | $0 | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | $500.0K | |
| Total Liabilities | $10M | $12M | $43M | $29M | $34M | $17M | $15M | $11M | $4M | |
| Long-term Debt | · | · | · | $15M | $15M | · | · | · | · | |
| Common Stock | $2.0K | $2.0K | $0 | $4.0K | $4.0K | $4.0K | $3.0K | $2.0K | · | |
| Paid-in Capital | $474M | $289M | $6M | · | · | · | · | · | · | |
| Retained Earnings | $-223M | $-149M | $-91M | $-489M | $-384M | $-264M | $-145M | $-72M | $-23M | |
| AOCI | $-96.0K | $9.0K | $-11.0K | · | · | · | · | · | · | |
| Stockholders' Equity | $251M | $141M | $-85M | $-46M | $169M | $254M | $186M | $122M | $-23M | |
| Liabilities + Equity | $261M | $153M | $39M | $104M | $204M | $271M | $201M | $133M | $7M | |
| Shares Outstanding | 18,738,249 | 14,856,309 | 1,407,753 | 43,916,000 | 43,652,000 | 43,652,000 | 31,643,000 | 23,806,628 | 2,305,173 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $1M | $1M | $1M | $1M | $850.0K | $380.0K | $45.0K | |
| Stock-based Comp | $10M | $3M | $1M | $12M | $19M | $16M | $7M | $2M | $177.0K | |
| Deferred Tax | $19M | $17M | $15M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Restructuring | · | · | $5M | · | · | · | · | · | · | |
| Other Non-cash | $-16M | $-23M | $-83M | $-4M | $1M | $4M | $-2M | $6M | · | |
| Operating Cash Flow | $-60M | $-59M | $-41M | $-97M | $-98M | $-99M | $-68M | $-38M | $-16M | |
| CapEx | $208.0K | $156.0K | $279.0K | $267.0K | $2M | $1M | $2M | $2M | $383.0K | |
| Investing Cash Flow | $-138.0K | $-156.0K | $-279.0K | $-267.0K | $-2M | $-1M | $-2M | $-2M | $-383.0K | |
| Debt Issued | · | · | · | $0 | $15M | · | · | · | · | |
| Net Debt Issued | · | · | · | $0 | $15M | · | · | · | · | |
| Stock Issued | · | · | $86.0K | $204.0K | · | · | $129M | $104M | · | |
| Net Stock Activity | · | · | $86.0K | · | · | · | $129M | · | · | |
| Financing Cash Flow | $173M | $172M | $34M | $262.0K | $30M | $173M | $130M | $160M | $17M | |
| Net Change in Cash | $113M | $112M | $-7M | $-97M | $-70M | $73M | $61M | $121M | $606.0K | |
| Taxes Paid | $1M | $0 | · | · | · | · | · | · | · | |
| Free Cash Flow | $-60M | $-59M | $-63M | $-97M | $-100M | $-100M | $-69M | $-39M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -35.8% | -60.3% | 11.9% | -68.8% | -50.1% | -50.7% | -43.7% | -66.0% | · | |
| ROE | -27.7% | -39.8% | 162.5% | -122.1% | -65.6% | -51.8% | -37.1% | -35.8% | · | |
| ROIC | -34.0% | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 26.6 | 12.6 | 15.8 | 7.6 | 10.3 | 16.1 | 14.0 | 12.3 | · | |
| Quick Ratio | 26.3 | 12.2 | 15.4 | 7.1 | 9.8 | 15.6 | 13.3 | 11.9 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $13.41 | $9.48 | $2.12 | $1.72 | $4.08 | $6.12 | $5.88 | $5.13 | · | |
| Cash Flow / Share | $-3.28 | $-6.96 | $-1.42 | $-2222.46 | · | · | · | · | · | |
| Cash / Share | $13.54 | $9.51 | $2.20 | $2.11 | $4.56 | $6.25 | $5.91 | $5.31 | · | |
| Dividend / Share | $0.00 | $0.00 | · | · | · | · | · | · | · | |
| EPS (TTM) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-74M | $-58M | $-43M | $-106M | $-119M | $-120M | $-73M | $-46M | · | |
| Market Cap | $391M | $686M | $729M | $374M | $1.92B | $6.95B | $7.64B | $4.76B | · | |
| P/E | -5.2 | -6.8 | -0.5 | -3.5 | -16.6 | · | · | · | · | |
| P/B | 1.6 | 4.9 | 7.7 | 5.0 | 11.3 | 27.3 | 41.1 | 38.9 | · | |
| P / Tangible Book | 1.6 | 4.9 | · | · | 11.3 | 27.3 | · | · | · | |
| P / Cash Flow | -6.5 | -11.6 | -11.5 | -3.8 | -19.6 | -70.4 | -113.0 | -126.3 | · | |
| P / FCF | -6.5 | -11.6 | -11.5 | -3.8 | -19.1 | -69.6 | -110.4 | -120.5 | · | |
| Earnings Yield | -19.4% | -14.8% | -206.9% | -28.4% | -6.0% | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $18M | $21M | $16M | $17M | $17M | $13M | $9M | $14M | $7M | $11M | $3M | $8M | $9M | $17M | $18M | $16M | |
| SG&A Expense | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $2M | $-11M | $6M | $5M | $8M | $7M | $7M | |
| Operating Expenses | $24M | $27M | $22M | $22M | $22M | $18M | $14M | $20M | $11M | $13M | $-1M | $10M | $11M | $25M | $25M | $23M | |
| Operating Income | $-24M | $-27M | $-22M | $-22M | $-22M | $-18M | $-14M | $-20M | $-11M | $-13M | $1M | $-10M | $-11M | $-25M | $-25M | $-23M | |
| Interest Income | $2M | $2M | $3M | $3M | $3M | $2M | $2M | $2M | $318.0K | $256.0K | $133.0K | $97.0K | $224.0K | · | · | · | |
| Other Non-op | $-5.0K | $-113.0K | $-8.0K | $-31.0K | $-48.0K | $-32.0K | $-96.0K | $-7.0K | $-5.0K | $-403.0K | $390.0K | $-1.0K | $-8.0K | $15.0K | $-321.0K | $-95.0K | |
| Pretax Income | $-22M | · | $-19M | $-19M | $-19M | · | $-12M | $-18M | $-13M | · | · | · | · | · | · | · | |
| Income Tax | $77.0K | · | $254.0K | $0 | $976.0K | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | · | · | |
| Net Income | $-22M | $-25M | $-19M | $-19M | $-20M | $-16M | $-12M | $-18M | $-13M | $-15M | $-8M | $-10M | $-10M | $-14M | $-25M | $-23M | |
| EPS (Basic) | $-1.18 | $-1.34 | $-1.03 | $-1.02 | $-1.07 | $-0.93 | $9.68 | $-1.20 | $-4.34 | $-10.97 | $-17.06 | $-7.62 | $-8.51 | $-0.57 | $-0.58 | $-0.52 | |
| EPS (Diluted) | $-1.18 | $-1.34 | $-1.03 | $-1.02 | $-1.07 | $-0.93 | $9.68 | $-1.20 | $-4.34 | $-10.97 | $-17.06 | $-7.62 | $-8.51 | $-0.57 | $-0.58 | $-0.52 | |
| Shares (Basic) | 18,964,008 | 18,769,004 | · | 18,712,767 | 18,680,042 | 17,157,661 | · | 14,729,018 | 2,919,872 | 1,387,303 | · | 1,319,147 | 1,228,778 | 44,037,000 | · | 43,773,000 | |
| Shares (Diluted) | 18,964,008 | 18,769,004 | · | 18,712,767 | 18,680,042 | 17,157,661 | · | 14,729,018 | 2,919,872 | 1,387,303 | · | 1,319,147 | 1,228,778 | 44,037,000 | · | 43,773,000 | |
| EBITDA | $-24M | $-27M | · | $-22M | $-22M | $-18M | · | $-20M | $-11M | $-8M | · | $-23M | $68M | $-25M | · | $-23M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $227M | $237M | $254M | $268M | $287M | $306M | $141M | $159M | $185M | $90M | $29M | $106M | $125M | $72M | $93M | $116M | |
| Prepaid Expense | $4M | $3M | $3M | $4M | $3M | $3M | $6M | $4M | $2M | $1M | $2M | $3M | $4M | $5M | $7M | $10M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | $626.0K | · | $805.0K | $792.0K | $845.0K | $1M | $765.0K | |
| Current Assets | $231M | $240M | $257M | $273M | $291M | $310M | $147M | $163M | $187M | $92M | $31M | $109M | $129M | $77M | $100M | $126M | |
| PP&E (Net) | $858.0K | $1M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | · | $3M | $0 | $2M | $3M | $3M | $3M | |
| PP&E (Gross) | · | · | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $5M | $7M | $7M | $7M | $7M | $7M | |
| Accum. Depreciation | · | · | $3M | $3M | $3M | $3M | $3M | $3M | $2M | · | $2M | $4M | $4M | $4M | $4M | $3M | |
| Other Non-current Assets | $626.0K | $663.0K | $640.0K | $597.0K | $287.0K | $138.0K | $156.0K | $190.0K | $13.0K | · | $31.0K | $40.0K | $40.0K | $40.0K | $40.0K | $41.0K | |
| Total Assets | $237M | $247M | $261M | $277M | $295M | $315M | $153M | $169M | $194M | $92M | $39M | $111M | $134M | $83M | $104M | $129M | |
| Accounts Payable | $2M | $3M | $1M | $1M | $3M | $6M | $976.0K | $3M | $4M | $243.0K | $409.0K | $910.0K | $1M | $591.0K | $384.0K | $2M | |
| Accrued Liabilities | $7M | $9M | $7M | $7M | $7M | $5M | $8M | $13M | $20M | $3M | $8M | $5M | $8M | $11M | $12M | $14M | |
| Current Liabilities | $10M | $13M | $10M | $9M | $11M | $14M | $12M | $17M | $26M | $4M | $41M | $8M | $12M | $14M | $13M | $16M | |
| Capital Leases | $3M | $3M | $0 | $0 | $0 | $0 | $132.0K | $523.0K | $905.0K | · | $2M | $105.0K | $134.0K | $352.0K | $188.0K | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Total Liabilities | $13M | $16M | $10M | $9M | $12M | $14M | $12M | $18M | $28M | $4M | $43M | $8M | $12M | $30M | $29M | $31M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $15M | · | $15M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $4.0K | $0 | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Paid-in Capital | $494M | $478M | $474M | $471M | $468M | $466M | $289M | $287M | $285M | · | $6M | · | · | · | · | · | |
| Retained Earnings | $-270M | $-248M | $-223M | $-204M | $-184M | $-164M | $-149M | $-136M | $-118M | $-484M | $-91M | $-468M | $-447M | $-514M | $-489M | $-464M | |
| AOCI | $0 | $0 | $-96.0K | $-75.0K | $-49.0K | $2.0K | $9.0K | $-77.0K | $-61.0K | · | $-11.0K | · | · | · | · | · | |
| Stockholders' Equity | $224M | $230M | $251M | $268M | $284M | $301M | $141M | $150M | $166M | $89M | $-85M | $103M | $122M | $53M | $75M | $98M | |
| Liabilities + Equity | $237M | $247M | $261M | $277M | $295M | $315M | $153M | $169M | $194M | $92M | $39M | $111M | $134M | $83M | $104M | $129M | |
| Shares Outstanding | 19,235,221 | 18,830,436 | 18,738,249 | 18,713,223 | 18,712,138 | 18,671,229 | 14,856,309 | 14,744,477 | 14,734,323 | 44,882,000 | 1,407,753 | 44,558,000 | 44,308,000 | 44,088,000 | 43,916,000 | 43,773,000 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $285.0K | $304.0K | $333.0K | $342.0K | $340.0K | $360.0K | $508.0K | $424.0K | $713.0K | $377.0K | $373.0K | $488.0K | $289.0K | $328.0K | $351.0K | $336.0K | |
| Stock-based Comp | $4M | $3M | $3M | $3M | $3M | $2M | $1M | $2M | $-154.0K | $321.0K | $294.0K | $-3M | $-2M | $3M | $2M | $3M | |
| Restructuring | · | · | · | · | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Other Non-cash | · | $3M | · | · | · | $360.0K | · | · | · | $-2M | · | · | · | $2M | · | · | |
| Operating Cash Flow | $-21M | $-18M | $-14M | $-18M | $-15M | $-13M | $-17M | $-20M | $-15M | $-9M | $-12M | $6M | $-259.0K | $-20M | $-24M | $-16M | |
| CapEx | $79.0K | $19.0K | $0 | $181.0K | $0 | $27.0K | $3.0K | $153.0K | $0 | $4.0K | $50.0K | $221.0K | $214.0K | $8.0K | $0 | $86.0K | |
| Investing Cash Flow | $-59.0K | $-19.0K | $0 | $-166.0K | $55.0K | $-27.0K | $-3.0K | $-153.0K | $0 | $-4.0K | $-50.0K | $-84M | $-214.0K | $-8.0K | $0 | $-86.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | $4.0K | · | $73.0K | $0 | $13.0K | $1.0K | $203.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $4.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $12M | $847.0K | $-141.0K | $-457.0K | $-4M | $178M | $-1M | $-6M | $179M | $-668.0K | $34M | $16M | $-324.0K | $55.0K | $59.0K | $60.0K | |
| Net Change in Cash | $-10M | $-17M | $-15M | $-18M | $-19M | $165M | $-18M | $-26M | $164M | $-10M | $22M | $-62M | $-797.0K | $-20M | $-24M | $-16M | |
| Free Cash Flow | · | $-18M | · | · | · | $-13M | · | · | · | $-8M | · | · | · | $-20M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -8.4% | -9.0% | · | -8.5% | -8.2% | -7.8% | · | -12.7% | -7.7% | -7.8% | · | -18.0% | 48.2% | -19.3% | · | -13.3% | |
| ROE | -8.8% | -9.5% | · | -9.1% | -8.9% | -8.2% | · | -14.0% | -8.8% | -9.6% | · | -21.5% | 56.1% | -25.4% | · | -15.8% | |
| ROIC | -10.9% | · | · | -8.2% | -8.3% | · | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 22.3 | 18.5 | · | 29.2 | 25.6 | 22.9 | · | 9.4 | 7.2 | 26.2 | · | 14.4 | 11.0 | 5.4 | · | 7.8 | |
| Quick Ratio | 21.9 | 18.3 | · | 28.6 | 25.3 | 22.7 | · | 9.2 | 7.1 | 25.8 | · | 14.0 | 10.7 | 5.1 | · | 7.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $11.64 | $12.24 | · | $14.30 | $15.16 | $16.12 | · | $10.20 | $11.29 | $1.98 | · | $2.31 | $2.75 | $1.20 | · | $2.24 | |
| Cash Flow / Share | · | $-0.98 | · | · | · | $-0.76 | · | · | · | $-0.17 | · | · | · | $-460.61 | · | · | |
| Cash / Share | $11.80 | $12.58 | · | $14.34 | $15.36 | $16.40 | · | $10.79 | $12.56 | $2.02 | · | $2.38 | $2.81 | $1.64 | · | $2.65 | |
| Dividend / Share | · | · | $0.00 | $0.00 | $0.00 | $0.00 | · | $0.00 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-4.57 | $-4.46 | · | $6.66 | $6.48 | $3.21 | · | $-33.57 | $-39.99 | $-44.16 | · | $-17.28 | $-10.18 | $-2.31 | · | $-2.49 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-86M | $-83M | · | $-67M | $-66M | $-59M | · | $-53M | $-46M | $-44M | · | $-60M | $-73M | $-91M | · | $-109M | |
| Market Cap | $661M | $582M | · | $294M | $372M | $331M | · | $447M | $243M | $689M | · | $823M | $505M | $529M | · | $336M | |
| P/E | -7.5 | -6.9 | · | 2.4 | 3.1 | 5.5 | · | -0.9 | -0.4 | -0.3 | · | -1.1 | -1.1 | -5.2 | · | -3.1 | |
| P/B | 3.0 | 2.5 | · | 1.1 | 1.3 | 1.1 | · | 3.0 | 1.5 | 7.8 | · | 8.0 | 4.1 | 10.0 | · | 3.4 | |
| P / Tangible Book | 3.0 | 2.5 | · | 1.1 | 1.3 | 1.1 | · | 3.0 | 1.5 | 7.8 | · | 8.0 | 4.1 | 10.0 | · | 3.4 | |
| P / Cash Flow | · | -31.6 | · | · | · | -25.3 | · | · | · | -91.1 | · | · | · | -26.1 | · | · | |
| Earnings Yield | -13.3% | -14.4% | · | 42.4% | 32.6% | 18.1% | · | -110.8% | -242.8% | -287.5% | · | -93.5% | -89.3% | -19.2% | · | -32.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-74M | $-58M | $-43M | $-106M | $-119M |
| Verwässerte EPS | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 26.6 | 12.6 | 15.8 | 7.6 | 10.3 |
| Quick Ratio | 26.3 | 12.2 | 15.4 | 7.1 | 9.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-60M | $-59M | $-63M | $-97M | $-100M |
Institutionelle Eigentümer (13F) 133 Einreicher · $488.8M gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
133
Gehaltener Wert
$488.8M
Neue Positionen
26
Geschlossene Positionen
10
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 26 (-3 vs. Vorquartal) | 10 (-8 vs. Vorquartal) | 39 (+3 vs. Vorquartal) | 41 (+4 vs. Vorquartal) | +85K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $97.294.233 | 2.830.378 | 19,90% | Aktien |
| TCG Crossover Management, LLC | $41.418.128 | 1.204.891 | 8,47% | Aktien |
| Aberdeen Group plc | $39.250.200 | 1.141.824 | 8,03% | Aktien |
| BlackRock, Inc. | $29.651.600 | 862.592 | 6,07% | Aktien |
| First Light Asset Management, LLC | $27.524.958 | 800.726 | 5,63% | Aktien |
| BAKER BROS. ADVISORS LP | $20.892.713 | 607.788 | 4,27% | Aktien |
| 5AM Venture Management, LLC | $20.853.938 | 606.660 | 4,27% | Aktien |
| BRAIDWELL LP | $20.518.438 | 596.900 | 4,20% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.802.672 | 488.805 | 3,44% | Aktien |
| Vestal Point Capital, LP | $14.609.375 | 425.000 | 2,99% | Aktien |
| VANGUARD GROUP INC | $12.513.872 | 599.898 | 2,56% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $9.700.694 | 282.202 | 1,98% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $9.299.108 | 270.461 | 1,90% | Aktien |
| ORBIMED ADVISORS LLC | $7.789.375 | 226.600 | 1,59% | Aktien |
| STATE STREET CORP | $7.559.338 | 219.908 | 1,55% | Aktien |
| Ikarian Capital, LLC | $7.075.647 | 205.837 | 1,45% | Aktien |
| D. E. Shaw & Co., Inc. | $6.412.656 | 186.550 | 1,31% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6.054.318 | 176.100 | 1,24% | Kaufoption |
| MARSHALL WACE, LLP | $5.916.833 | 172.101 | 1,21% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $5.689.922 | 165.525 | 1,16% | Aktien |
| Squarepoint Ops LLC | $4.985.338 | 145.028 | 1,02% | Aktien |
| AMERIPRISE FINANCIAL INC | $4.896.673 | 142.448 | 1,00% | Aktien |
| WELLS FARGO & COMPANY/MN | $4.036.588 | 117.428 | 0,83% | Aktien |
| NORTHERN TRUST CORP | $3.915.450 | 113.904 | 0,80% | Aktien |
| Soleus Capital Management, L.P. | $3.495.388 | 101.684 | 0,72% | Aktien |
| Woodline Partners LP | $3.437.500 | 100.000 | 0,70% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.245.481 | 94.414 | 0,66% | Aktien |
| CITADEL ADVISORS LLC | $3.107.260 | 90.393 | 0,64% | Aktien |
| GOLDMAN SACHS GROUP INC | $2.541.138 | 73.924 | 0,52% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $2.498.169 | 72.674 | 0,51% | Aktien |
| SECTORAL ASSET MANAGEMENT INC | $2.440.934 | 71.009 | 0,50% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.351.044 | 68.394 | 0,48% | Aktien |
| JANE STREET GROUP, LLC | $2.262.596 | 65.821 | 0,46% | Aktien |
| MORGAN STANLEY | $2.247.205 | 65.373 | 0,46% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $2.232.313 | 64.940 | 0,46% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.089.003 | 60.771 | 0,43% | Aktien |
| JPMORGAN CHASE & CO | $1.831.995 | 55.364 | 0,37% | Aktien |
| KOTLER KEVIN | $1.668.800 | 80.000 | 0,34% | Aktien |
| Tetragon Partners GP Ltd | $1.598.988 | 46.516 | 0,33% | Aktien |
| PFM Health Sciences, LP | $1.568.566 | 45.631 | 0,32% | Aktien |
| Jump Financial, LLC | $1.491.875 | 43.400 | 0,31% | Aktien |
| Prosight Management, LP | $1.365.753 | 39.731 | 0,28% | Aktien |
| Trexquant Investment LP | $1.271.566 | 36.991 | 0,26% | Aktien |
| Aldebaran Capital, LLC | $1.264.897 | 36.797 | 0,26% | Aktien |
| ExodusPoint Capital Management, LP | $1.211.341 | 35.239 | 0,25% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $1.080.475 | 31.432 | 0,22% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.046.306 | 30.438 | 0,21% | Aktien |
| MONIMUS CAPITAL MANAGEMENT, LP | $967.416 | 28.143 | 0,20% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $965.673 | 41.463 | 0,20% | Aktien |
| Bank of New York Mellon Corp | $867.872 | 25.247 | 0,18% | Aktien |
Aktivisten & 5%+-Eigentümer 6 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Timothy A. Springer, TAS Partners LLC, Chafen Lu ×5 Einreichungen | 7. April 2025 | 31,50% | Änderung | · | SEC |
| Terrance McGuire, Polaris Partners IX, L.P., Polaris Partners GP IX, L.L.C., Polaris Founders Capital Fund I, L.P., Polaris Founders Capital Fund Management Co. I, L.L.C., Polaris Founders Capital Fund II, L.P., Polaris Founders Capital Fund Management Co. II, L.L.C., Jonathan Flint ×3 Einreichungen | 7. April 2025 | 6,30% | Änderung | · | SEC |
| Vida Ventures II, LLC, Vida Ventures II-A, LLC, VV Manager II, LLC ×3 Einreichungen | 7. April 2025 | 0,00% | Änderung | · | SEC |
| ATLAS VENTURE FUND X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC ×2 Einreichungen | 28. Oktober 2024 | · | Erste Einreichung | · | SEC |
| SVLSF VI, LLC, SV Life Sciences Fund VI, L.P., SV Life Sciences Fund VI Strategic Partners, L.P., SV Life Sciences Fund VI (GP), L.P. ×2 Einreichungen | 16. Februar 2021 | · | Erste Einreichung | · | SEC |
| Clarus Lifesciences III, L.P., Clarus Ventures III GP, L.P., Blackstone Clarus III L.L.C., Blackstone Holdings II L.P., Blackstone Holdings I/II GP L.L.C., The Blackstone Group Inc., Blackstone Group Management L.L.C., Stephen A. Schwarzman ×4 Einreichungen | 6. August 2019 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 33 Insider · 17 Führungskräfte · 15 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alise Reicin | Chief Executive Officer | 25. September 2026 F | 309.078 | 2 | 0 | $105.500 |
| Erik Ostrowski | Interim CEO, President and CFO | 1. Februar 2024 M | 29.285 | 0 | 0 | $0 |
| Geoffrey Mackay | President & CEO | 8. Februar 2023 A | 188.012 | 0 | 0 | $0 |
| Daniel Lochner | Chief Financial Officer | 25. September 2026 F | 58.024 | 1 | 0 | $129.660 |
| Katina Dorton | Chief Financial Officer | 8. Oktober 2018 M | 10.000 | 0 | 0 | $0 |
| Birgitte Volck | President of R&D | 4. März 2020 A | · | 0 | 0 | $0 |
| Christian Cortis | Chief Operating Officer | 20. Juni 2024 A | 126.368 | 0 | 0 | $0 |
| Peter Mcnamara | Chief Scientific Officer | 30. September 2026 S | 54.305 | 0 | 8 | $-288.006 |
| Marcella K. Ruddy | Chief Medical Officer | 25. September 2026 F | 67.157 | 0 | 3 | $-363.000 |
| Marc Schwabish | Chief Business Officer | 25. September 2026 F | 44.903 | 0 | 0 | $0 |
| Azadeh Golipour | Chief Technology Officer | 1. Februar 2024 M | 55.872 | 0 | 0 | $0 |
| Essra Ridha | Chief Medical Officer | 1. Februar 2024 M | 15.881 | 0 | 0 | $0 |
| Steven Avruch | Chief Legal Officer | 1. Februar 2024 M | 22.022 | 0 | 0 | $0 |
| Deanna M Petersen | Chief Business Officer | 8. Februar 2023 A | · | 0 | 0 | $0 |
| Christopher Mason | Chief Scientific Officer | 10. Juni 2021 A | · | 0 | 0 | $0 |
| Diana Escolar | Chief Medical Officer | 10. Juni 2021 A | · | 0 | 0 | $0 |
| Nerissa Kreher | Chief Medical Officer | 8. Oktober 2018 M | 2.942 | 0 | 0 | $0 |
| Stefan Vitorovic | Direktor | 9. Juni 2026 A | 27.774 | 0 | 0 | $0 |
| Praveen P. Tipirneni | Direktor | 9. Juni 2026 A | 3.037 | 0 | 0 | $0 |
| Phillip B. Donenberg | Direktor | 9. Juni 2026 A | 2.000 | 0 | 0 | $0 |
| Timothy A. Springer | Direktor | 9. Juni 2026 A | 1.503.358 | 0 | 0 | $0 |
| Jessica Caroline Chutter | Direktor | 8. Juni 2026 A | · | 0 | 0 | $0 |
| Terrance McGuire | Direktor | 9. Juni 2025 A | 573.062 | 0 | 0 | $0 |
| Christopher Paige | Direktor | 6. Juni 2023 A | 252.512 | 0 | 0 | $0 |
| Annalisa Jenkins | Direktor | 6. Juni 2023 A | · | 0 | 0 | $0 |
| Philip J. Vickers | Direktor | 6. Juni 2023 A | 4.800 | 0 | 0 | $0 |
| Gail M Farfel | Direktor | 6. Juni 2023 A | · | 0 | 0 | $0 |
| Bruce Booth | Direktor | 6. Juni 2023 A | 5.567.289 | 0 | 0 | $0 |
| Ian T Clark | Direktor | 6. Juni 2023 A | · | 0 | 0 | $0 |
| Scott Requadt | Direktor | 25. Juni 2018 C | 2.962.325 | 0 | 0 | $0 |
| ATLAS VENTURE ASSOCIATES X, L.P. | 10%-Eigentümer | 13. Februar 2020 J | 3.710.052 | 0 | 0 | $0 |
| Francois Nader | · | 1. April 2026 A | · | 0 | 0 | $0 |
| Leonard Braden Michael | · | 20. Juni 2024 J | 33.333 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 20 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,62% | 10.265 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 34.693 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 1.415 SH | 23. Oktober 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 7.356 SH | 19. August 2026 | Täglich |
| IBB · iShares Trust | 0,02% | 70.963 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 58.897 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 264.002 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 4.882 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 19.539 SH | 11. September 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,00% | 371 NS | 31. Juli 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 7.996 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 5.450 SH | 3. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 975 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 1.127 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 111.919 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 364.413 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.713 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.002 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 25.446 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 77.593 SH | 11. September 2026 | Täglich |
TECX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 15 Analysten
KAUF
Median-Ziel
$76.00
+278,7%
6 40,0%
Starker Kauf
8 53,3%
Kauf
1 6,7%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
9 Analysten · 2026-10-24Mittelwert-Ziel $71.00 +253,8%
← Unter allen Zielen
Aktueller Preis $20.07
Tief$26.00
Mittelwert$71.00
Hoch$93.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026